- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about CRSP
Recent news which mentions CRSP
2 No-Brainer Biotech Stocks to Buy Right Now
December 22, 2022
From Motley Fool
3 Cathie Wood Stocks That Could Make Big Comebacks in 2023
December 22, 2022
From Motley Fool
3 Growth Stocks That Are Screaming Buys in December
December 21, 2022
From Motley Fool
Better Bear Market Buy: Vertex Pharmaceuticals vs. Biogen Stock
December 18, 2022
From Motley Fool
3 Beaten-Down Stocks That Could Explode Higher in 2023
December 17, 2022
From Motley Fool
7 Stocks to Add to Your 10x Watchlist
December 16, 2022
Tags
RENT
NASDAQ:SNGX,NASDAQ:RENT,NASDAQ:SFIX,NASDAQ:KSCP,NASDAQ:CRSP,NASDAQ:HARP,NASDAQ:MVST,NYSE:DTC
SNGX
From InvestorPlace
3 Growth Stocks With More Potential Than Any Cryptocurrency
December 15, 2022
From Motley Fool
3 Red-Hot Stocks That Could Continue to Beat the Market
December 11, 2022
From Motley Fool
Want to Be Ready For a New Bull Market? Do These 3 Things Soon
December 09, 2022
From Motley Fool
2 Growth Stocks That Could Help Set You Up for Life
December 09, 2022
From Motley Fool
5 Best Bargain Stocks to Buy Before 2023
December 09, 2022
From Motley Fool
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
December 08, 2022
From Motley Fool
Is CRISPR Therapeutics a Buy?
December 08, 2022
From Motley Fool
Precigen's Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy
December 08, 2022
From Benzinga
2 Unstoppable Growth Stocks to Buy in 2022 and Beyond
December 08, 2022
From Motley Fool
Why a Biotech ETF Might Cure Your Portfolio in 2023
December 07, 2022
From ETF Trends
3 Fierce Stocks That Are Screaming Buys in December
December 07, 2022
From Motley Fool
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
December 06, 2022
From Motley Fool
Bear Market Bargain Hunting: 3 Top Stocks to Buy Before 2023
December 06, 2022
From Motley Fool
3 Growth Stocks That Are Too Cheap to Ignore
December 01, 2022
From Motley Fool
2 Stocks Near 52-Week Highs That Could Climb Higher
November 28, 2022
From Motley Fool
Cathie Wood Is Selling This High-Flying Stock. Here's Why You Should Buy It Instead
November 25, 2022
From Motley Fool
What 5 Analyst Ratings Have To Say About CRISPR Therapeutics
November 23, 2022
Tickers
CRSP
From Benzinga
From Benzinga
Where Will Editas Medicine Be in 1 Year?
November 20, 2022
From Motley Fool
2 Growth Stocks That Could Double in 2023
November 17, 2022
From Motley Fool
Crispr Therapeutics Stock: Bull vs. Bear
November 15, 2022
From Motley Fool
5 Top Stocks to Buy Before 2023
November 15, 2022
From Motley Fool
Vertex Pharmaceuticals: Buy at the High?
November 14, 2022
From Motley Fool
Want $1 Million in Retirement? Invest $100,000 in These 3 Stocks and Wait a Decade
November 12, 2022
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.